Gregg Fine

• Daniel S. Chen7
• Priti S. Hegde7
• Thomas Powles7
• Howard A. Burris6
• Marcin Kowanetz5
• Michael S. Gordon5
• Ahmad Mokatrin4
• Daniel P. Petrylak4
• David F. McDermott4
• Hartmut Koeppen4
• Jean‐Charles Soria4
• Joaquim Bellmunt4
• Omid Hamid4
• Yohann Loriot4
• Dorothee Nickles3
• F. Stephen Hodi3
• Jeffrey A. Sosman3
• John D. Powderly3
• Mario Sznol3
• Richard W. Joseph3
• Roy S. Herbst3
• Sanjeev Mariathasan3
• Xiaodong Shen3
• Zachary Boyd3

1. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

   Authors: Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe Yuen, Yulei Wang, Edward E. Kadel, Hartmut Koeppen, Jillian L. Astarita, Rafael Cubas, Suchit Jhunjhunwala, Romain Banchereau, Yagai Yang, Yinghui Guan, Cécile Chalouni, James Ziai, Yasin Şenbabaoğlu, Stephen P. Santoro, Daniel Sheinson, Jeffrey Hung, Jennifer M. Giltnane, Andrew A. Pierce, Kathryn Mesh, Steve Lianoglou, Johannes Riegler, Richard A.D. Carano, Pontus Eriksson, Mattias Höglund, Loan Somarriba, Daniel L. Halligan, Michiel S. van der Heijden, Yohann Loriot, Jonathan E. Rosenberg, Lawrence Fong, Ira Mellman, Daniel S. Chen, Marjorie Green, Christina Louise Derleth, Gregg Fine, Priti S. Hegde, Richard Bourgon, Thomas Powles - Nature 2018 cited by 5,616

2. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

   Authors: Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Gregg Fine, Omid Hamid, Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott Gettinger, Holbrook E. Kohrt, Leora Horn, Donald P. Lawrence, Sandra Rost, Maya K. Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, Daniel S. Chen, F. Stephen Hodi - Nature 2014 cited by 5,302

3. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

   Authors: Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer - The Lancet 2016 cited by 3,714

4. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

   Authors: Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman‐Censits, José Luis Perez‐Gracia, Nancy A. Dawson, Michiel S. van der Heijden, Robert Dreicer, Sandy Srinivas, Margitta Retz, Richard W. Joseph, Alexandra Drakaki, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. Quinn, Ignacio Durán, David R. Shaffer, Bernhard J. Eigl, Petros Grivas, Evan Y. Yu, Shi Li, Edward E. Kadel, Zachary Boyd, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin - The Lancet 2016 cited by 2,211

5. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

   Authors: David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles - Nature Medicine 2018 cited by 1,250

6. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

   Authors: Thomas Powles, Joseph P. Eder, Gregg Fine, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz, Joaquim Bellmunt, Howard A. Burris, Daniel P. Petrylak, Siew-leng Melinda Teng, Xiaodong Shen, Zachary Boyd, Priti S. Hegde, Daniel S. Chen, Nicholas J. Vogelzang - Nature 2014 cited by 2,430

7. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

   Authors: Juanita Lopez, Thomas Powles, Fadi Braiteh, Lillian L. Siu, Patricia LoRusso, Claire F. Friedman, Ani Sarkis Balmanoukian, Michael Gordon, Jeffrey Yachnin, Sylvie Rottey, Ioannis Karydis, George A. Fisher, Marcus Schmidt, Martin Schüler, Ryan J. Sullivan, Howard A. Burris, Vladimir Galvao, Brian S. Henick, Luc Dirix, Dirk Jaeger, Patrick A. Ott, Kit Man Wong, Guy Jérusalem, Aglaia Schiza, Lawrence Fong, Neeltje Steeghs, Rom S. Leidner, Achim Rittmeyer, Scott A. Laurie, Eelke Gort, Raid Aljumaily, Ignacio Melero, Rachel Lubong Sabado, Ina Rhee, Michael R. Mancuso, Lars Müller, Gregg Fine, Mahesh Yadav, Leesun Kim, Vincent J. P. Leveque, Alberto Robert, Martine Darwish, Ting Qi, Jiawen Zhu, Jingbin Zhang, Patrick Twomey, Gautham K. Rao, Donald W. Low, Christoph Petry, Amy A. Lo, Jill Schartner, Lélia Delamarre, Ira Mellman, Martin Löwer, Felicitas Müller, Evelyna Derhovanessian, Andrea Cortini, Luisa Manning, Daniel Maurus, Sebastian Brachtendorf, Verena Lörks, Tana Omokoko, Eva Godehardt, Dirk Becker, Christine Hawner, Christine Wallrapp, Christian Albrecht, Christoph Kröner, Arbel D. Tadmor, Jan Diekmann, Mathias Vormehr, Anette Jork, Anna Paruzynski, Maren Lang, Jonathon Blake, Oliver Hennig, Andreas N. Kuhn, Uğur Şahin, Özlem Türeci, D. Ross Camidge - Nature Medicine 2025 cited by 96

8. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

   Authors: F. Stephen Hodi, Marcus Ballinger, Benjamin Lyons, Jean‐Charles Soria, Mizuki Nishino, Josep Tabernero, Thomas Powles, David C. Smith, Axel Hoos, Chris McKenna, Ulrich Beyer, Ina Rhee, Gregg Fine, Nathan Winslow, Daniel S. Chen, Jedd D. Wolchok - Journal of Clinical Oncology 2018 cited by 374

9. Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

   Authors: David F. McDermott, Jeffrey A. Sosman, Mario Sznol, Christophe Massard, Michael S. Gordon, Omid Hamid, John D. Powderly, Jeffrey R. Infante, Marcella Fassò, Yan V. Wang, Wei Zou, Priti S. Hegde, Gregg Fine, Thomas Powles - Journal of Clinical Oncology 2016 cited by 558

10. Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

    Authors: Alexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, E. Andrés Houseman, Shan Zhong, Jaegil Kim, Michael J. Nathenson, Thomas Faitg, Mary Woessner, David C. Turner, Aisha Hasan, John Glod, Rosandra N. Kaplan, Sandra P. D’Angelo, Dejka M. Araujo, Warren Chow, Mihaela Druta, George D. Demetri, Brian A. Van Tine, Stephan A. Grupp, Gregg Fine, Ioanna Eleftheriadou - Nature Communications 2022 cited by 52

11. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

    Authors: Bharathi Vennapusa, Brian M. Baker, Marcin Kowanetz, Jennifer Boone, Ina Menzl, Jean‐Marie Bruey, Gregg Fine, Sanjeev Mariathasan, Ian McCaffery, Simonetta Mocci, Sandra Rost, Dustin Smith, Eslie Dennis, Szu‐Yu Tang, Bita Damadzadeh, Espen J. Walker, Priti S. Hegde, J. Andrew Williams, Hartmut Koeppen, Zachary Boyd - Applied immunohistochemistry & molecular morphology 2018 cited by 189

12. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

    Authors: Roy S. Herbst, Michael S. Gordon, Gregg Fine, Jeffrey A. Sosman, Jean‐Charles Soria, Omid Hamid, John D. Powderly, Howard A. Burris, Ahmad Mokatrin, Marcin Kowanetz, Maya K. Leabman, Maria Anderson, Daniel S. Chen, F. Stephen Hodi - Journal of Clinical Oncology 2013 cited by 191

13. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation

    Authors: William W. Cruikshank, Kaiser G. Lim, Arthur C. Theodore, Jennifer Cook, Gregg Fine, P F Weller - The Journal of Immunology 1996 cited by 133

14. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction

    Authors: Arthur C. Theodore, John Nicoll, Gregg Fine, Hardy Kornfeld, William W. Cruikshank - The Journal of Immunology 1996 cited by 106

15. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

    Authors: Laurie H. Sehn, Sarit Assouline, Douglas A. Stewart, Joy Mangel, Randy D. Gascoyne, Gregg Fine, Susan Frances-Lasserre, David Carlile, Michael Crump - Blood 2012 cited by 147

16. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).

    Authors: Thomas Powles, Nicholas J. Vogelzang, Gregg Fine, Joseph P. Eder, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz Zambrano, Joaquim Bellmunt, Howard A. Burris, Siew-leng Melinda Teng, Xiaodong Shen, Hartmut Koeppen, Priti S. Hegde, Daniel S. Chen, Daniel P. Petrylak - Journal of Clinical Oncology 2014 cited by 96

17. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

    Authors: David R. Spigel, Scott Gettinger, Leora Horn, Roy S. Herbst, Leena Gandhi, Michael S. Gordon, Cristina Cruz, Paul Conkling, Philippe A. Cassier, Scott Antonia, Howard A. Burris, Gregg Fine, Ahmad Mokatrin, Marcin Kowanetz, Xiaodong Shen, Daniel S. Chen, Jean‐Charles Soria - Journal of Clinical Oncology 2013 cited by 90

18. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).

    Authors: Daniel C. Cho, Jeffrey A. Sosman, Mario Sznol, Michael S. Gordon, Antoine Hollebecque, Omid Hamid, David F. McDermott, Jean‐Pierre Delord, Ina Rhee, Ahmad Mokatrin, Marcin Kowanetz, Roel Funke, Gregg Fine, Thomas Powles - Journal of Clinical Oncology 2013 cited by 97

All 18 papers shown.